Clinical trials: Essential Hypertension.
Stage 2 Systolic Hypertension
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood…
- Trial name
- EXALT (NCT00931710)
- Testing
- valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
- Where
- United States
- Volunteers
- 488 people
- Sponsor
- Novartis
Hypertension
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
The primary objective of this study was to assess the anti-hypertensive effect of OM/HCTZ 40/12.5 mg combination therapy compared to OM 40 mg monotherapy in lowering sitting diastolic BP in hypertensive patients after 8 weeks of…
- Trial name
- NCT00441350
- Testing
- OM 40, OM/HCTZ 40/12.5
- Where
- 65 sites in Croatia, Czechia and 6 more
- Volunteers
- 1,004 people
- Sponsor
- Menarini Group
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Hypertension
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks
- Trial name
- NCT00260923
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 641 people
- Sponsor
- Novartis
Hypertension
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
To evaluate the trough and peak effect of once daily MICARDIS PLUS (Telmisartan 80 mg/hydrochlorothiazide 12.5 mg) by 24 ABPM in patients with mild to moderate essential hypertension.
- Trial name
- NCT00257491
- Testing
- Telmisartan, Telmisartan/HCTZ
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
High Blood Pressure (Hypertension).
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
The purpose of this research study is to determine if treatment with the combination of metoprolol succinate and hydrochlorothiazide is more effective at lowering blood pressure than treatment with either of the two drugs alone.
- Trial name
- NCT00642096
- Testing
- Metoprolol Succinate, Hydrochlorothiazide
- Volunteers
- 1,900 people
- Sponsor
- AstraZeneca
Primary Hypertension
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension
The purpose of this study is to assess the safety and efficacy of renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension in China.
- Trial name
- NCT03511313
- Testing
- Renal denervation, Renal angiography
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Synaptic Medical Corporation
Hypertension
Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to provide long-term data on its impact on liver function, glucose homoeostasis and lipid metabolism.
- Trial name
- NCT02177331
- Testing
- Lacidipine
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Study of CS-3150 in Patients With Essential Hypertension
To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.
- Trial name
- ESAX-HTN (NCT02890173)
- Testing
- CS-3150, Eplerenone
- Where
- Japan
- Volunteers
- 1,001 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Essential Hypertension
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
- Trial name
- ALIAS (NCT01042392)
- Testing
- Aliskiren, Ramipril
- Where
- 98 sites in France
- Volunteers
- 506 people
- Sponsor
- Novartis
Essential Hypertension
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential…
- Trial name
- NCT06671392
- Testing
- DWC202405, DWC202405, DWC202314, DWC202405, DWC202314P
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus, Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06226727
- Testing
- BR1019, BR1019-1, BR1019-2
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
CKD-828 S-Amlodipine Non-Responder Trial
The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg) in hypertensive patients inadequately…
- Trial name
- NCT01501253
- Testing
- CKD-828 2.5/40mg, CKD-828 2.5/80mg, S-Amlodipine 2.5mg
- Where
- South Korea
- Volunteers
- 187 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
- Trial name
- NCT00846365
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
- Where
- 80 sites in United States, Chile and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Takeda
Essential Hypertension
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.
- Trial name
- NCT02206165
- Testing
- Candesartan 8mg, Candesartan 16mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 456 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential…
- Trial name
- BENEFIT (NCT03847350)
- Where
- South Korea
- Volunteers
- 3,250 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Essential Hypertension
A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers
To evaluate drug-drug interaction between fimasartan and hydrochlorothiazide.
- Trial name
- NCT00923533
- Testing
- Fimasartan, Hydrochlorothiazide
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)
This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.
- Trial name
- NCT01431508
- Testing
- Losartan 50 mg / HCTZ 12.5 mg
- Volunteers
- 15 people
- Sponsor
- Organon and Co
Essential Hypertension
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
- Trial name
- NCT01131546
- Testing
- Levamlodipine besylate, Amlodipine maleate
- Where
- China
- Volunteers
- 1,080 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Hypertension
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
This study will evaluate the pharmacokinetic profile, the effect of rennin inhibition and the relationship among pharmacokinetics, renin-angiotensin system (RAS) biomarkers, and blood pressure lowering effects of oral doses of…
- Trial name
- NCT00424541
- Testing
- SPP100 (aliskiren)
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Novartis